The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Hepatology

Volumn 55, Issue 6, 2012, Pages 2005-2023

  Chalasani, Naga ^a   Younossi, Zobair ^b   Lavine, Joel E ^c   Diehl, Anna Mae ^d   Brunt, Elizabeth M ^e   Cusi, Kenneth ^f   Charlton, Michael ^g   Sanyal, Arun J ^h  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d DUKE UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g MAYO CLINIC   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; AMIODARONE; CORTICOSTEROID; CYTOKERATIN 18; INSULIN SENSITIZING AGENT; METFORMIN; METHOTREXATE; OMEGA 3 FATTY ACID; PEGINTERFERON; PIOGLITAZONE; PLACEBO; RIBAVIRIN; ROSIGLITAZONE; TAMOXIFEN; URSODEOXYCHOLIC ACID;

ALCOHOL CONSUMPTION; ARTICLE; BARIATRIC SURGERY; BODY MASS; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FAMILY HISTORY; FATTY LIVER; GASTROENTEROLOGY; GENE MUTATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CELL; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; MEDICAL SOCIETY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; METFORMIN; PREVALENCE; RISK FACTORS; THIAZOLIDINEDIONES; VITAMIN E;

EID: 84861543083     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25762     Document Type: Article

References (198)

1. Eddy DM. A manual for assessing health practices and designing practice guidelines. Philadelphia. American College of Physicians. 1996; 1-126.
2. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
3. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: selected practical issues in their management. Hepatology 2009; 49: 306-317.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
5. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788.
6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
7. Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine 2011; 43(8): 617-49.
8. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
9. Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005; 41(1): 64-71.
10. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005; 143(10): 722-8.
11. Whalley S, Puvanachandra P, Desai A, Kennedy H. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med. 2007; 7(2): 119-24.
12. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007; 47(2): 239-44.
13. Marcos A, Fischer RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME, Posner MP. Transplantation 2000; 69: 2410-2415.
14. Williams CD, Stenger J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
15. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387-95.
16. Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JI, Raddatz A, Guzman S, Arrese M. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005; 15: 1148-53.
17. Haentjens P, Massaad D, Reynaert H, Peeters E, Van Meerhaeghe A, Vinken S, Poppe K, Velkeniers B. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. Acta Clin Belg. 2009; 64: 483-93.
18. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006; 45: 600-6.
19. Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C, Conca P, Contaldo F, Pasanisi F. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab. 2005; 49: 289-95.
20. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003; 138: 1240-4.
21. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009; 29: 113-9.
22. Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, Shah SR, Rathi PM, Joshi AS, Thakkar H, Menon PS, Shah NS. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009; 57: 205-10.
23. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45: 1929-1934.
24. Li H, Wang YJ, Tan K, Zeng L, Liu L, Liu FJ, Zhou TY, Chen EQ, Tang H. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat Dis Int. 2009; 8(4): 377-82.
25. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007; 6(3): 161.
26. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006; 21(1 Pt 1): 138-43.
27. Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009; 55(6): 607-13.
28. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol. 2007; 22: 1482-9.
29. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008; 49: 608-12.
30. Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, Shiratori K. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005; 33(2): 72-6.
31. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 l; 129: 113-21.
32. Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008 Aug; 9(8): 616-22.
33. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98: 960-7.
34. Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, Cotler SJ. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci. 2008; 53: 1358-63.
35. Wagenknecht LE, Scherzinger AL, Stamm ER, Hanley AJ, Norris JM, Chen YD, Bryer-Ash M, Haffner SM, Rotter JI. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity 2009; 17: 1240-6.
36. Fischer GE, Bialek SP, Homan CE, Livingston SE, McMahon BJ. Chronic liver disease among Alaska-Native people, 2003-2004. Am J Gastroenterol. 2009; 104: 363-70.
37. Bialek SR, Redd JT, Lynch A, Vogt T, Lewis S, Wilson C, Bell BP. Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000-2003. J Clin Gastroenterol. 2008; 42: 949-54.
38. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999 Jun; 116(6): 1413-9.
39. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004 May; 53(5): 750-5.
40. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44: 865-73.
41. W Dunn, R Xu, D Wingard, C Rogers, P Angulo, ZM Younossi, JB Schwimmer. Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-based Cohort Study. Am J of Gastroenterology 2008; 103: 2263-71.
42. N Rafiq, CH Bai, Y Fang, M Srishord, A McCullough, T Gramlich, ZM Younossi. Long-Term Follow-Up of Patients with Non-Alcoholic Fatty Liver. Clinical Gastro and Hepatology 2009; 7: 234-8.
43. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009; 44(10): 1236-43.
44. M Stepanova, N Rafiq, ZM. Younossi. Components of metabolic syndrome as independent predictors of mortality in chronic liver disease: A population-based study. Gut. 2010; 59 (10): 1410-5.
45. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010; 51: 595-602.
46. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004; 40: 578-84.
47. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol. 2004; 99: 292-8.
48. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123: 134-40.
49. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009; 44 Suppl 19: 89-95.
50. Smedile A, Bugianesi E. Steatosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci. 2005; 9: 291-3.
51. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol. 2010; 16: 1436-41.
52. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factor of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978.
53. Yasui K, Hashimoto E, Komorizono Y, Koike S, Arli S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-433.
54. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-427.
55. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 42: 132-138.
56. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254.
57. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis. An international collaborative study. Hepatology 2011; 54(4): 1208-16.
58. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley DE, Chalasani N, Lavine JE, Ratziu V, McCullough A. End points and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353.
59. Liagnpunsakul S, Chalasani N. What do we recommend our patients with NAFLD about alcohol consumption? Am J Gastroenterol 2012 (In press).
60. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108: 9-13.
61. Willner IR, Walters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-2961.
62. Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree delatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 1162-1169.
63. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136: 1585-1592.
64. Kowdley KV. The role of iron in nonalcoholic fatty liver disease: the story continues. Gastroenterology 2010; 138: 817-819.
65. Bacon BR, Adams PC, Kowdley KV, Powell PW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328 - 343.
66. Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N, Kowdley KV. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2011; ePub ahead of print.
67. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
68. Kang H, Greenson JK, Omo JT et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006; 101: 2247-2253.
69. Ryan MC, Wilson AM, Slavin J et al. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1222-1224.
70. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
71. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt DA, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
72. Wieckowski A, McCullough AJ, Feldstein AE. Noninvasis diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. HEPATOLOGY 2007; 46: 582-589.
73. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991; 12: 224-229.
74. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990; 99: 1408-1413.
75. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci. 1995; 10: 414-421.
76. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997; 27: 103-107.
77. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-419.
78. Sreenivasa Baba CS, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2006; 21: 191-198.
79. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004; 53: 413-419.
80. Suzuki A, Lindor K, Saver J, Lymp J, Mendes F, Muto A, Okada T, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005; 43: 1060-1066.
81. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, Teramo K, Yki-Jarvinen H. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003; 52: 701-707.
82. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2005; 90: 3191-196.
83. Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab. 2005; 90: 2804-2809.
84. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005; 54: 603-608.
85. Larson-Meyer DE, Heilbronn LK, Redman LM, Newcomer BR, Frisard MI, Anton S, Smith SR, Alfonso A, Ravussin E. Effect of calorie restriction with or without exercise on insulin sensitivity, □-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006; 29: 1337-1344.
86. Thomas EL, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, Frost G, Bell JD, Taylor-Robinson SD. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5813-5819.
87. Thamer C, Machann J, Stefan N, Haap M, Schafer S, Brenner S, Kantartzis K, Claussen C, Schick F, Haring H, Fritsche A. High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity 2007; 15: 531-538.
88. Schafer S, Kantartzis K, Machann J, Venter C, Niess A, Schick F, et al. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest 2007; 37: 535-543.
89. Cowin GJ, Jonsson JR, Bauer JD, Ash S, Ali A, Osland EJ, Purdie DM, Clouston AD, Powell EE, Galloway GJ. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008; 28: 937-945.
90. Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, Lefevre M, Rood JC, Williamson DA, Ravussin E. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity 2008; 16: 1355-1362.
91. Viljanen AP, Iozzo P, Borra R, Kankaanpa M, Karmi A, Lautamaki R, Jarvisalo M, Parkkola R, Ronnemaa T, Guiducci L, Lehtimaki T, Raitakari OT, Mari A, Nuutila P. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab 2009; 94: 50-55.
92. Kantartzis 2009 Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009; 58: 1281-1288.
93. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136: 1552-1560.
94. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn S, Clark JM, for the Fatty Liver Subgroup of the Look Ahead Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33: 2156-2163.
95. Wang R, Koretz R, Yee H. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med. 2003; 115: 554-559.
96. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.
97. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Amer J Gastroenterol. 2005; 100: 1072-1081.
98. Tendler D, Lin S, Yancy WS, Jr., Mavropoulos J, Sylvestre P, Rockey DC, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Digestive Diseases & Sciences. 2007; 52: 589-93.
99. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006; 4: 639-44.
100. Harrison SA, Brunt EM, Fecht WJ, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial. Hepatology 2009; 49: 80-86.
101. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129.
102. Shojaee-Moradie F, Baynes KC, Pentecost C, Bell JD, Thomas EL, Jackson NC, et al. Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia 2007; 50: 404-413.
103. Bonekamp S, Barone BB, Clark J, Stewart KJ. The effects of an exercise training intervention on hepatic steatosis [Abstract]. Hepatology 2008; 48(Suppl.): 806A.
104. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-1112.
105. van der Heijden GJ, Wang ZJ, Chu ZD, Sauer PJ, Haymond MW, Rodriguez LM, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity 2010; 18: 384-390.
106. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001; 358: 893-4.
107. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004; 19: 537-44.
108. Nair S, Diehl AM, Wiseman M, Farr GH, Jr., Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004; 20: 23-8.
109. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100: 1082-90.
110. Loomba, R., Lutchman, G., Kleiner, D.E., Ricks, M., Feld, J.J. et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-182.
111. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot study. Therap Adv Gastroenterol 2009; 2: 157-63.
112. Haukeland JW, Konopski Z, Eggesbø HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-60.
113. Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 200-208.
114. Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007; 6: 222-226.
115. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol. 2009; 46: 113-8.
116. Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yimaz C, Akarca U. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. European J Gastroenterol Hepatology. 2010; 22: 18-23.
117. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003; 38: 1008-17.
118. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-110.
119. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, LeNaour G, Hartemann-Heurtier A, Bruckert E and Poynard T for the LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-453.
120. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355: 2297-307.
121. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-1184.
122. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
123. Lincoff A, Wolski K, Nicholls S, Nissen S: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
124. Hasegawa T, et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with nonalcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-1672.
125. Harrison SA, et al. Vitamin E and vitamin C treatment improves fibrosis is patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490.
126. Dufour JF, et al. Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543.
127. Sanyal AJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-1115.
128. Yakaryilamz F, et al. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis, results of a pilot study. Intern Med J 2007; 37: 229-235.
129. Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Meta-analysis: antioxidant supplements for liver disease - the Cochrane Hepato-Biliary Group. Aliment Pharmacol Ther 2010; 32: 356-367.
130. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, et al for the Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305: 1659-68.
131. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersmara, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
132. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements of primary and secondary prevention: systematic review and meta-analysis JAMA. 2007 Feb 28; 297(8): 842-57. Review. Erratum in: JAMA. 2008 Feb 20;299(7):765-766.
133. Berry D, Wathen JK, Newell M. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin Trials 2009; 6: 28-41.
134. Gerss J, Kopcke W. The questionable association of vitamin E supplementation and mortality - inconsistent results of different meta-analytic approaches. Cell Mol Biol 2009; 55 Suppl: OL 1111-20.
135. Dietrich M, Jacques PF, Pencina MJ, Lanier K, Keyes MJ, Kaur G, Wolf PA, D'Agostino RB, Vasan RS. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? Atherosclerosis 2009; 205: 549-553.
136. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011; 306: 1549-1556.
137. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-1467.
138. Leushner U, Lindenthal B, Herrman G, Arnold JC, Rossle M, Cordes H-J, et al. High-dose Ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-479.
139. Lindor KD, Kowldey KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-778.
140. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, et al. A randomized controlled trial of hig-dose ursogeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54: 1011-1019.
141. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Alimentary pharmacology & therapeutics 2006; 23: 1143-11 51.
142. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics 2010; 31: 679-692.
143. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A, Romon M, Pattou F. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced liver disease. Gastroenterology 2009; 137: 532-540.
144. Mummadi RR, Kasturi KS, Chennareddygair S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clinical Gastro and Hepatol 2008; 6: 1396-1402.
145. Chavez-Tapia NC, Tellez-Avila FI, Barrientose-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database of Systematic Reviews 2010, Issue 1. Art No: CD007340. DOI:10:1002/14641858.
146. (Accessed 1/18/2012).
147. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008; 47: 1947-1954.
148. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am J Gastroenterol 2009; 104: 2189-2195.
149. Suzuki A, Angulo P, St. Sauver J, Muto A, Okada T, Lindor K. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol 2007; 102: 1912-1919.
150. Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, Ikeda F, Shiratori Y, Yamamoto K. Alcohol consumption appears to protect against non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 378-388.
151. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
152. Cotrim HP, Freitas LA, Alves E, Almeida A, May DS, Caldwell S. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 2009; 21: 969-972.
153. Dunn W, Brunt EM, Sanyal AJ, McCullough AJ, Unalp A, Tonascia J, Schwimmer J. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease (NAFLD). Hepatology 50, 390A. 2009.
154. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Seminars in Liver Disease 2012; 32: 22-29.
155. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 128: 1287-1292.
156. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62-65.
157. Chalasani N. Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease. Hepatology 2005; 41: 690-695.
158. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-471.
159. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R; Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007; 46: 1453-63.
160. Horlander JC, Kwo PY, Cummings OW, Koukoulis G. Atorvastatin for the treatment of NASH. Gastroenterology 2001; 120 (Supplement); 2767.
161. Gomer-Dominguez E, Gisbert JP, Moreno-Monteagudo A, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-1647.
162. Antonopoulos S, Mikros S, Mylonopoulos M, Kokkoris M, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233-234.
163. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St. Francis Heart Study Randomized Clinical Trial. Am J Gastroenterol 2011; 106: 71-77.
164. Athyros VG, Mikhalidis DP, Didangelos TP, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Curr Med Res Opin 2006; 22: 872-883.
165. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP, for the GREACE Study Collaborative Group. Lancet 2010; 376; 1916-1922.
166. Ekstedt M, Franzen L, Mathiesen UL, Holmqvist M, Bodemar G, Kehagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-141.
167. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990-994.
168. Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histological features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16: 49-56.
169. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
170. Petta S, Camma C, Di Marco V, Macaluso FS, Maida M, Pizzolanti G, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV. Liver Int 2011; 31: 507-511.
171. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Alimen Pharmacol Ther 2011; 34: 297-305.
172. Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Tarantino L, et al. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. J Gastroenterol 2010; 45: 1053-1062.
173. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
174. Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepa 2008; 15: 129-136.
175. Negro F, Clements S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy to hepatitis C. J Viral Hepat 2009; 16: 681-688.
176. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie A, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364; 2405-2416.
177. Zeuzam S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
178. Bacon BR, Gordon SC, Lawtiz E, Marcellin P, Vierling J, Zeuzam S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364-1207-1217.
179. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011l 364-1195-1206.
180. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
181. Garcia-Tsao G, Sanyal J, Grace ND, Carey WD, for the Practice Guidelines Committee of the American Association for the Study of Liver Disease and the Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007; 102: 2086-2102.
182. Bruix J, Sherman M. Management of Hepatocellular carcinoma: An update. Hepatology 2011; Mar; 53(3): 1020-1022.
183. Schwimmer J, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006; 118; 1388-1393.
184. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-649.
185. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009; 58: 1538-1544.
186. Riley MR, Bass NM, Rosenthal P, Merriman RB. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr. 2005; 147: 839-842.
187. Patton H, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J for the NASH-CRN. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis (NASH). Gastroenterology, 2008; 135: 1961-1971.
188. Barlow SE and the Expert Committee. Expert Committee Recommendations Regarding the Preventions, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report. Pediatrics vol 120, 2007; S164-192.
189. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009; 50: 1282-1293.
190. Alkhouri N, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, Feldstein AE, Nobili V. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol. 2011; 9: 150-155.
191. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM. Performance oof ELF serum markers in predicting serum fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136: 160-167.
192. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
193. Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ, Feldstein AE. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology. 2009; 50: 1113-1120.
194. Ko JS, Yoon JM, Yang HR, Myung JK, Kim HR, Kang GH, Cheon JE, Seo JK. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci. 2009; 54: 2225-30.
195. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Camporcola D, et al. NAFLD in children: A prospective clinical-pathological study and effect of lifestyle. HEPATOLOGY 2006: 458-465.
196. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119-128.
197. Barlow SE, Dietz WH. Management of child and adolescent obesity: summary and recommendations based on reports from pediatricians, pediatric nurse practitioners, and registered dietitians. Pediatrics 2002; 110: 236-238.
198. Grundy SM. Cleeman JI. Daniels SR. Donato KA. Eckel RH. Franklin BA. Gordon DJ. Krauss RM. Savage PJ. Smith SC Jr. Spertus JA. Costa F. American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 112(17): 2735-52, 2005 Oct 25.